Market Cap 1.15B
Revenue (ttm) 358.71M
Net Income (ttm) 23.39M
EPS (ttm) N/A
PE Ratio 11.40
Forward PE 9.27
Profit Margin 6.52%
Debt to Equity Ratio 0.63
Volume 530,800
Avg Vol 742,886
Day's Range N/A - N/A
Shares Out 63.02M
Stochastic %K 52%
Beta 0.40
Analysts Strong Sell
Price Target $36.20

Company Profile

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 238 9600
Address:
1350 Old Bayshore Highway, Suite 400, Burlingame, United States
Stmkr
Stmkr Oct. 24 at 2:52 PM
$INVA Have they talked about plans for sulbactam/durlobactam in Europe?
0 · Reply
Stmkr
Stmkr Oct. 24 at 1:31 PM
$INVA Interesting company
0 · Reply
All4Retiring
All4Retiring Oct. 22 at 5:08 PM
$INVA own 69% of $ARMP Armata's Blood-Infection Drug Shows Positive Results in Mid-Stage Trial - MarketWatch
2 · Reply
tilance
tilance Oct. 22 at 1:52 PM
$INVA opened a position here today
0 · Reply
Billybob1977
Billybob1977 Oct. 21 at 3:39 AM
$ITRM Setup looks more like a merger to me right now. $INVA
0 · Reply
DirkInvest
DirkInvest Oct. 17 at 2:31 PM
$INVA Started a small position, seems undervalued to me. Not too interested in the upcoming PDUFA though, I dont think it will be significant for revenue.
0 · Reply
Tain0os
Tain0os Oct. 10 at 8:38 PM
$SPY $CSPX (Ireland S&P 500) firm long at the EU open tomorrow. Opened Q4 net longs today -> $RGNX $OMER $INVA $AXGN
1 · Reply
All4Retiring
All4Retiring Oct. 8 at 3:53 PM
$INVA Bought more shares today. Drug resistance pharmaceuticals is an underserved and high demand sector. Very long until buyout.
0 · Reply
ZeroDayZealot
ZeroDayZealot Oct. 5 at 7:59 AM
$INVA Insurance services stability. Testing key support level. Volume pattern shows accumulation. Dividend yield supportive.
0 · Reply
ninergizer
ninergizer Sep. 30 at 8:59 PM
$INVA starting a new long position today as well options 20 Call Exp Dec 19th. PDUFA Date: Dec 15, 2025 Zoliflodacin — Oral antibiotic for gonorrhea FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). Market Impact: Medium–large public health value, smaller direct commercial revenue. U.S. gonorrhea cases ~700k/year (CDC). New oral option = government/NGO contracts, global demand, less private pricing power. Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.
0 · Reply
Latest News on INVA
Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Oct 21, 2025, 8:00 AM EDT - 4 days ago

Antheia Appoints Eric d'Esparbes as Chief Financial Officer


Innoviva to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:00 AM EDT - 2 months ago

Innoviva to Participate in Upcoming Investor Conferences


Innoviva: Underappreciated Strength In Hospital Therapeutics

Feb 23, 2025, 1:11 AM EST - 8 months ago

Innoviva: Underappreciated Strength In Hospital Therapeutics


10 stocks you can bet on being inflation-proof

Feb 28, 2024, 2:48 PM EST - 1 year ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN


Innoviva: A Lot Of Moving Parts

Oct 9, 2023, 1:48 PM EDT - 2 years ago

Innoviva: A Lot Of Moving Parts


Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 25, 2023, 4:52 PM EDT - 2 years ago

Innoviva Appoints Stephen Basso as Chief Financial Officer


FDA approves Innoviva's bacterial pneumonia treatment

May 23, 2023, 10:32 PM EDT - 2 years ago

FDA approves Innoviva's bacterial pneumonia treatment


Innoviva Announces Retirement of Board Chairman

Apr 28, 2023, 5:30 PM EDT - 2 years ago

Innoviva Announces Retirement of Board Chairman


Innoviva Stock Trading Halted Today

Apr 17, 2023, 9:00 AM EDT - 2 years ago

Innoviva Stock Trading Halted Today


Stmkr
Stmkr Oct. 24 at 2:52 PM
$INVA Have they talked about plans for sulbactam/durlobactam in Europe?
0 · Reply
Stmkr
Stmkr Oct. 24 at 1:31 PM
$INVA Interesting company
0 · Reply
All4Retiring
All4Retiring Oct. 22 at 5:08 PM
$INVA own 69% of $ARMP Armata's Blood-Infection Drug Shows Positive Results in Mid-Stage Trial - MarketWatch
2 · Reply
tilance
tilance Oct. 22 at 1:52 PM
$INVA opened a position here today
0 · Reply
Billybob1977
Billybob1977 Oct. 21 at 3:39 AM
$ITRM Setup looks more like a merger to me right now. $INVA
0 · Reply
DirkInvest
DirkInvest Oct. 17 at 2:31 PM
$INVA Started a small position, seems undervalued to me. Not too interested in the upcoming PDUFA though, I dont think it will be significant for revenue.
0 · Reply
Tain0os
Tain0os Oct. 10 at 8:38 PM
$SPY $CSPX (Ireland S&P 500) firm long at the EU open tomorrow. Opened Q4 net longs today -> $RGNX $OMER $INVA $AXGN
1 · Reply
All4Retiring
All4Retiring Oct. 8 at 3:53 PM
$INVA Bought more shares today. Drug resistance pharmaceuticals is an underserved and high demand sector. Very long until buyout.
0 · Reply
ZeroDayZealot
ZeroDayZealot Oct. 5 at 7:59 AM
$INVA Insurance services stability. Testing key support level. Volume pattern shows accumulation. Dividend yield supportive.
0 · Reply
ninergizer
ninergizer Sep. 30 at 8:59 PM
$INVA starting a new long position today as well options 20 Call Exp Dec 19th. PDUFA Date: Dec 15, 2025 Zoliflodacin — Oral antibiotic for gonorrhea FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). Market Impact: Medium–large public health value, smaller direct commercial revenue. U.S. gonorrhea cases ~700k/year (CDC). New oral option = government/NGO contracts, global demand, less private pricing power. Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Sep. 21 at 10:37 PM
List of all commercial-stage oncology & non-oncology (over $100MM MC) M&A for those with 1st FDA approvals going back to 1/1/2013. 88% of commercial-stage oncology sold at gains were sold within 2 years of FDA approval. It is 91% in non-oncology over 33 months. Because new drugs are worth the net present value of their future sales thru patent expiration, new drugs become less valuable over time as patent life is generally always nearing. Because approval rates are dismal, we can count on 2 hands commercial-stage bios that have scored a second approval of a drug with a meaningful commercial opportunity or a label extension. Of course there are exceptions like $ASND & $INSM but the odds are long. The evidence is overwhelming shareholders are best served via M&A exit as soon as possible after FDA approval. $IOVA & $GERN are textbook examples of new comm'l-stage bios with credible label extension potential. $INVA ? Pushback/feedback? This is not investment advice.
3 · Reply
Biorocksme
Biorocksme Sep. 11 at 3:45 PM
$ITRM not impressed $INVA -3.3% today
0 · Reply
look2theblue
look2theblue Sep. 11 at 1:33 PM
$ITRM With the vote behind us, the team will likely be forced to sell the company. The question is how much and to whom? I think $2-2.50 is best case at this point. And either to $PFE $GSK or $INVA Still a respectable return, but not the $5 most expected.
4 · Reply
All4Retiring
All4Retiring Sep. 8 at 7:11 PM
$INVA I have owned this stock a few years and I don’t recall their involvement in so many investment conferences.
0 · Reply
Doozio
Doozio Sep. 5 at 3:52 PM
$INVA it still is. Surviving bahhhh ride. 🐒🍌🧠⏰♾️
0 · Reply
ArbitrageArena
ArbitrageArena Aug. 27 at 9:56 AM
$INVA choppy movement, waiting for clearer direction.
0 · Reply
jimbowills
jimbowills Aug. 26 at 2:13 PM
$AXGN $INVA Two solid picks right now. Don't miss the run
1 · Reply
They_Call_Me_Tater_Salad
They_Call_Me_Tater_Salad Aug. 22 at 6:00 PM
$INVA In for 10k shares at $20.11. No brainer here.
0 · Reply
JarvisFlow
JarvisFlow Aug. 11 at 11:30 AM
Oppenheimer has updated their rating for Innoviva ( $INVA ) to Outperform with a price target of 35.
0 · Reply
JarvisFlow
JarvisFlow Aug. 11 at 11:00 AM
HC Wainwright & Co. has adjusted their stance on Innoviva ( $INVA ), setting the rating to Buy with a target price of 40 → 45.
0 · Reply
All4Retiring
All4Retiring Aug. 6 at 9:31 PM
0 · Reply
All4Retiring
All4Retiring Aug. 6 at 9:30 PM
$INVA Earnings posted on IR website. Link below https://investor.inva.com/node/20806/pdf
0 · Reply